HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2001
Business Overview: Provider of enabling tools for drug discovery research, including spectrophotometers, plate readers, and ADMET screening products. The company operates globally with significant manufacturing and sales in the U.S., U.K., and Germany.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Net loss for the nine-month period includes significant non-cash charges related to acquisitions.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 40% ($3.0 million) for the quarter and 31% ($6.9 million) for the nine months compared to the prior year periods. Approximately 75% of the quarterly growth was attributed to acquisitions.
• Profitability Shift: The company reported a net income of $0.3 million for the quarter, a significant improvement from a net loss of $17.2 million in the same period in 2000. The nine-month net loss narrowed to $4.8 million from $84.0 million in 2000.
• Expense Drivers:
  • Stock Compensation: Decreased significantly to $0.7 million (quarter) and $2.2 million (nine months) from $13.1 million and $13.3 million respectively in 2000, following the IPO.
  • Acquisition Costs: The nine-month period included a $5.4 million charge for in-process research and development (IPR&D) related to the Union Biometrica and Warner Instruments acquisitions.
  • Warrant Interest: The 2000 period included a massive $70.9 million non-cash warrant interest expense, which was eliminated in 2001 following the IPO and warrant exercise.
• Acquisitions: The company completed three major acquisitions in the second quarter of 2001: Warner Instruments ($2.7M), Union Biometrica ($17.5M valuation), and IMS ($1.7M).

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects cash proceeds from the IPO, available cash ($30.2 million), and operating cash flows to be sufficient to finance operations and capital expenditures for at least two years from September 30, 2001.
• Capital Needs: The company may need to raise additional capital to accelerate product development, expand sales, or make further acquisitions. Future equity raises could dilute existing shareholders.
• Legal Proceedings: Harvard University is suing the company for trademark infringement regarding the names "Harvard Bioscience" and "Harvard Apparatus." While the court denied a preliminary injunction to stop the use of the names, it ordered the company not to use the name in crimson or a specific font. Management believes the defense will not have a material adverse effect.
• Accounting Changes: The company is evaluating the impact of new FASB pronouncements (SFAS 141, 142, 143, 144) regarding business combinations, goodwill, and asset retirement obligations.
• Subsequent Event: On November 1, 2001, the company acquired Scie-Plas Ltd. for approximately $4.0 million.

Investor Verification Checklist

• Acquisition Integration: Verify the revenue contribution and integration progress of Union Biometrica, Warner Instruments, and IMS, which drove 75% of recent revenue growth.
• Trademark Litigation: Monitor the status of the Harvard University lawsuit and potential costs or brand impact, despite the current court order.
• Non-Cash Charges: Confirm the treatment of the $5.4 million IPR&D charge and ensure future periods do not carry similar one-time acquisition costs.
• Cash Burn vs. Runway: Assess the $13.2 million cash used in investing activities against the $30.2 million cash balance to validate the two-year liquidity runway claim.
• Goodwill Amortization: Review the impact of new accounting standards (SFAS 142) on future goodwill amortization expenses, which were $1.1 million for the nine months ended 9/30/01.